This distribution reflects the current trends in immunotherapy treatments for cancer, particularly the widespread use of pembrolizumab and nivolumab compared to that of ipilimumab (anti-CTLA-4) due to their side-effect profiles and their proven efficacy for treatment of various types of cancer [30,31]. The gene discussed is CTLA4; the disease is cancer.